Business Wire November 30, 2021
GE

Collaborations with SOPHiA GENETICS, The University of Cambridge and Optellum are intended expand access to the latest and most advanced technologies for cancer care

CHICAGO–(BUSINESS WIRE)–GE Healthcare announced collaborations with SOPHiA GENETICS, The University of Cambridge and Optellum as part of its vision to advance care, make precision health more accessible, and ultimately improve outcomes for cancer patients.

“Cross-functional partnerships between organizations are key to the creation of new approaches and intelligent tools that enable cancer to be detected as early as possible and with the greatest degree of accuracy”

Tweet this

These alliances are intended to help GE Healthcare support integrated health systems at the local level by providing the technology to...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Patient / Consumer, Pharma / Biotech, Precision Medicine, Provider
Related Articles:
Answer ALS, Cedars-Sinai Collaboration, Single-Cell Protein Profiling, ChapsVision Acquires Sinequa, More
Pharma Pulse 11/25/24: Deepening Patient Relationships,
Halozyme abandons its €2bn pursuit of Evotec
BridgeBio poised to challenge Pfizer after Attruby approval
Halozyme Pulls €2B Acquisition Bid as Evotec Commits to Standalone Strategy

Share This Article